Trade Emergent BioSolutions Inc. - EBS CFD
Add to favourite- Summary
- Historical Data
| Spread | 0.14 | ||||||||
|
Long position overnight fee
Long position overnight funding adjustment
Go to platform | -0.02629% | ||||||||
|
Short position overnight fee
Short position overnight funding adjustment
Go to platform | 0.004068% | ||||||||
| Overnight fee time | 21:00 (UTC) | ||||||||
| Min traded quantity | 1 | ||||||||
| Currency | USD | ||||||||
| Margin | 5.00% | ||||||||
| Stock exchange | United States of America | ||||||||
| Commission on trade | 0% |
| Prev. Close | 13.79 |
| Open | 14 |
| 1-Year Change | 100.57% |
| Day's Range | 13.49 - 14.17 |
- Last Week
- Last Month
- Last Year
- Last two Years
- Max
- Daily
- Weekly
- Monthly
| Date | Close | Change | Change (%) | Open | High | Low |
|---|---|---|---|---|---|---|
| Jul 26, 2024 | 13.87 | -0.08 | -0.57% | 13.95 | 14.22 | 13.42 |
| Jul 25, 2024 | 13.78 | -0.32 | -2.27% | 14.10 | 14.54 | 13.49 |
| Jul 24, 2024 | 13.73 | 1.53 | 12.54% | 12.20 | 13.93 | 11.86 |
| Jul 23, 2024 | 12.45 | 0.94 | 8.17% | 11.51 | 12.60 | 11.41 |
| Jul 22, 2024 | 11.42 | 0.37 | 3.35% | 11.05 | 11.49 | 10.59 |
| Jul 19, 2024 | 11.12 | -0.04 | -0.36% | 11.16 | 11.93 | 11.01 |
| Jul 18, 2024 | 11.38 | -0.55 | -4.61% | 11.93 | 12.15 | 11.03 |
| Jul 17, 2024 | 12.01 | -0.08 | -0.66% | 12.09 | 12.69 | 10.89 |
| Jul 16, 2024 | 12.08 | 0.68 | 5.96% | 11.40 | 12.32 | 11.19 |
| Jul 15, 2024 | 11.29 | 0.30 | 2.73% | 10.99 | 11.72 | 10.65 |
| Jul 12, 2024 | 10.64 | 0.72 | 7.26% | 9.92 | 10.92 | 9.76 |
| Jul 11, 2024 | 9.86 | 0.46 | 4.89% | 9.40 | 10.20 | 9.10 |
| Jul 10, 2024 | 9.24 | 0.50 | 5.72% | 8.74 | 9.27 | 8.53 |
| Jul 9, 2024 | 8.66 | 0.57 | 7.05% | 8.09 | 8.84 | 7.99 |
| Jul 8, 2024 | 8.10 | 0.16 | 2.02% | 7.94 | 8.41 | 7.89 |
| Jul 5, 2024 | 7.91 | 0.45 | 6.03% | 7.46 | 7.95 | 7.40 |
| Jul 3, 2024 | 7.49 | -0.09 | -1.19% | 7.58 | 7.62 | 6.95 |
| Jul 2, 2024 | 7.48 | 0.36 | 5.06% | 7.12 | 8.26 | 7.09 |
| Jul 1, 2024 | 7.05 | 0.30 | 4.44% | 6.75 | 7.17 | 6.66 |
| Jun 28, 2024 | 6.78 | -0.14 | -2.02% | 6.92 | 7.32 | 6.77 |
Trading calculator
Calculate your hypothetical P&L if you had opened a CFD trade on a certain date (select a date) and closed on a different date (select a date).
- 1:1
- 20
- 100
- 500
- 1000
- 10000
Emergent BioSolutions Company profile
Emergent BioSolutions Inc., a life sciences company, focuses on the provision of specialty products for civilian and military populations that address accidental, deliberate, and naturally occurring public health threats (PHTs). Its products address PHTs, which include chemical, biological, radiological, nuclear, and explosives; emerging infectious diseases; travel health; and emerging health crises and acute/emergency care. The company offers BioThrax, an anthrax vaccine; ACAM2000, a smallpox vaccine; Vaxchora, a cholera vaccine; and Vivotif, a typhoid vaccine. It also provides NARCAN for the emergency treatment of known or suspected opioid overdose; Reactive Skin Decontamination Lotion Kit, a medical device to remove or neutralize chemical warfare agents from the skin; and Trobigard a combination drug-device auto injector product candidate. In addition, the company offers raxibacumab for the treatment and prophylaxis of inhalational anthrax; Anthrasil to treat inhalational anthrax; Botulism Antitoxin Heptavalent for treating botulinum disease; vaccinia immune globulin intravenous that addresses complications from smallpox vaccination; CHIKUNGUNYA, a chikungunya virus-like particle vaccine; and ADENOVIRUS 4/7. Further, it offers other discovery and preclinical product candidates addressing PHTs, including viral hemorrhagic fevers caused by Ebola, Marburg, Sudan, and Lassa viruses; diarrheal disease caused by Shigella; and heat-labile toxin producing enterotoxigenic Escherichia coli, etc. Additionally, the company offers FLU-IGIV to treat Influenza A infection; and ZIKV-IG, a prophylaxis for Zika infections, as well as contract development and manufacturing services to pharma and biotech industries, and government agencies/non-governmental organizations. Emergent BioSolutions Inc. has a development and manufacturing agreement with Novavax Inc. for coronavirus disease vaccine candidate. The company was founded in 1998 and is headquartered in Gaithersburg, Maryland.| Industry: | Pharmaceuticals (NEC) |
400 Professional Dr, Suite 400
GAITHERSBURG
MARYLAND 20879
US
News
How to manage risk when trading
Learn what risk management is and find out how understanding about it could help you identify potential risks in your investment portfolio. Find out more.
06:57, 22 July 2024
ECB preview: lack of new data sees markets expecting a hold
Markets expect the ECB to keep rates unchanged in July but expectations for a September cut rise
13:13, 18 July 2024
What is an IPO and how does it work?
Learn about what an IPO is, why they are important, and how they work.
07:19, 10 July 2024
What are the biggest stock exchanges worldwide?
Discover the largest stock exchanges in the world by market capitalisation, including the Nasdaq Stock Market, the New York Stock Exchange and the London Stock Exchange.
12:44, 9 July 2024
Top ETFs
ETFs, or exchange-traded funds, offer traders a versatile gateway into the financial markets.
16:23, 8 July 2024
Lloyds forecast: will Lloyds share price return to £1? Third party data forecast
What’s next for Lloyds amid higher inflation and the start of a potential recessionary cycle in the UK?
14:00, 8 July 2024
RBNZ Preview: OCR expected to remain unchanged as central bank focuses on inflation
The Reserve Bank of New Zealand meets on Wednesday, July 10, 2024. We preview what to expect from the meeting and its possible impact on the NZD/USD.
13:25, 8 July 2024People also watch
Still looking for a broker you can trust?
Join the 630,000+ traders worldwide that chose to trade with Capital.com